Tempest secures $2.5M upfront in private placement
Tempest Therapeutics entered a private placement expected to provide $2.5M upfront, with up to another $5M possible only if warrants are exercised.
Small biotech financings often come with headline numbers that overstate the cash actually reaching a company on day one.
What happened
Tempest Therapeutics entered definitive agreements for a private placement expected to generate approximately $2.5M in gross proceeds upfront. Series C and Series D warrants could provide up to roughly $5M of additional proceeds if fully exercised, but there is no assurance that those warrants will be exercised.
Why it matters
For a clinical-stage biotech, even relatively small financing can extend operating runway while development programmes progress. But the distinction between committed cash and potential warrant proceeds matters when assessing a company’s actual funding position.
The bigger picture
Biotech financing remains selective, particularly for smaller public companies. Structured placements, warrants and equity facilities are increasingly common tools for raising incremental capital when a large conventional follow-on round may not be available.